Skip to search formSkip to main contentSkip to account menu

AC 7700

Known as: AVE8062, Combretastatin A4 Analogue AVE8062, AC7700 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
Tumor vasculature is an important target in cancer treatment. Two distinct vasculartargeting therapeutic strategies are applied… 
Review
2009
Review
2009
Angiogenesis has an essential role in promoting and supporting tumor growth and it is an important therapeutic target. The tumor… 
Highly Cited
2008
Highly Cited
2008
Objectives:To evaluate the early tumor vasculature disrupting effects of the AVE8062 molecule and the feasibility of dynamic… 
Review
2007
Review
2007
  • S. Cai
  • Recent patents on anti-cancer drug discovery
  • 2007
  • Corpus ID: 25873315
Vascular disrupting agents (VDAs) are a new class of potential anticancer drugs that selectively destroy tumor vasculature and… 
Highly Cited
2007
Highly Cited
2007
The purpose of this study was to examine the therapeutic efficacy and underlying mechanisms of action of a vascular-disrupting… 
Review
2004
Review
2004
  • P. Thorpe
  • Clinical Cancer Research
  • 2004
  • Corpus ID: 1739027
Vascular targeting agents (VTAs) for the treatment of cancer are designed to cause a rapid and selective shutdown of the blood… 
Highly Cited
2003
Highly Cited
2003
We previously reported that a novel combretastatin A-4 derivative, AC7700, has remarkable antitumour effects because of an… 
Review
2002
Review
2002
The tumour vasculature is an attractive target for therapy. Combretastatin A‐4 (CA‐4) and A‐1 (CA‐1) are tubulin binding agents… 
Highly Cited
2002
Highly Cited
2002
In a previous study, we used subcutaneous LY80 tumours (a subline of Yoshida sarcoma), Sato lung carcinoma, and… 
Highly Cited
1999
Highly Cited
1999
AC‐7700, a novel combretastatin A‐4 derivative, suppresses the growth of solid tumors by inhibiting tumor perfusion. We evaluated…